Related Experiment Video
Updated: Feb 18, 2026
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
8.6K
Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events
Michael Beck1, Derralynn Hughes2, Christoph Kampmann1
1University Medical Center, Mainz, Germany.
Molecular Genetics and Metabolism Reports
|November 22, 2017
Summary
Enzyme replacement therapy with agalsidase alfa shows varied Fabry disease progression. Cardiac events occurred earlier in males, while females experienced more cerebrovascular events.
Area of Science:
- Biochemistry
- Genetics
- Internal Medicine
Background:
- Fabry disease is a rare genetic disorder.
- Enzyme replacement therapy (ERT) is a treatment option.
- Agalsidase alfa is a specific ERT used for Fabry disease.
Purpose of the Study:
- To analyze the long-term effects of agalsidase alfa ERT.
- To examine cerebrovascular, cardiac, and renal morbidity in Fabry patients.
- To identify age- and sex-specific differences in disease progression.
Main Methods:
- Retrospective analysis of the Fabry Outcome Survey database.
- Inclusion of 677 pediatric and adult patients receiving agalsidase alfa.
- Median follow-up duration of 3 years.
Main Results:
- Cardiac events occurred at earlier ages compared to cerebrovascular or renal events.
- Cerebrovascular events were more prevalent in female patients.
- Males experienced cardiac and renal events at younger ages than females.
Conclusions:
- Agalsidase alfa ERT impacts disease progression differently across age and sex.
- Understanding these differences is crucial for tailored Fabry disease management.
- Further research into sex-specific treatment responses is warranted.
